Traditional stainless steel bioreactors remain the preferred choice for late-stage clinical development and large-scale commercial manufacturing due to their high level of automation, established processes, and lower long-term operating costs. However, their high upfront investment, lengthy facility construction timelines, and complex cleaning validation requirements can limit production flexibility.

Single-use bioreactors, by comparison, eliminate the need for complex cleaning and sterilization procedures, significantly reducing cross-contamination risks and simplifying validation requirements. With strong alignment with GMP expectations, single-use technology has become increasingly important as biopharmaceutical development accelerates and manufacturers seek greater flexibility for multi-product production.  Combining decades of experience in reactor design with state-of-the-art single-use technology, Bioengineering introduces the Bagento Single-Use Bioreactor, a flexible and efficient platform designed to support modern bioprocessing needs.

Bagento Single-Use Bioreactor

One system. Many applications.

Bagento creates the environment in which cell cultures can reach their full potential.

• No cleaning or sterilization validation

• Scalable platform from 50 to 2000 L

• Multi-product operation on the same production line

• Faster time to market

• Flexible system configuration for individual processes

1.Modular Design with Seamless Scaling

Bagento is a comprehensive one-stop solution, supporting a wide variety of culture modes such as batch, fed-batch, and perfusion, and enables seamless scaling from 50 to 2000 liters.

2.Superior Mixing Performance and Reliable Sterility Assurance

Integrated mechanical stirring elements ensure excellent mixing and optimal mass transfer. By eliminating time-consuming cleaning and validation steps, the Bagento minimizes setup times and eliminates the risk of cross-contamination. It provides a reliable solution for both antibodies and vaccines, guaranteeing the highest standards of product quality.

3. Highly Stable Single-Use Culture Bags

These highly stable, gamma-sterilized, and tested-to-all-standard specifications single-use culture bags are suitable for the cultivation of many cell lines for protein expression, immunotherapy, or vaccine production. They are easy to handle, suitable for batch, fedbatch,and perfusion processes, and reliably enable high cell densities.

4. BioScada II – Intuitive SCADA for controlling bioprocesses

BioScada II visualizes and analyzes your bioprocess in real time. Freely configurable widgets display critical process parameters, trends and system states exactly where they are needed. Integrated analysis tools enable fast comparison of batches and support data-driven process optimization.

• Freely configurable widgets for process visualization

• Integrated analyzer with batch-tobatch trend comparison

• Setpoint Selector for intuitive cascade control configuration

• Flexible setpoint profiles (e.g. exponential feed strategies)

• Integrated sequencer for custom process workflows

• Remote Service Provider for secure system monitoring and support

As the biopharmaceutical industry continues to evolve toward multi-product portfolios, smaller production batches, and personalized therapies, flexible and responsive manufacturing platforms have become critical competitive advantages. With its integrated modular design and intelligent process control capabilities, the Bagento Single-Use Bioreactor helps reduce capital investment and operational risks while providing a reliable pathway for technology transfer from R&D to commercial manufacturing. By accelerating process development and production readiness, Bagento supports faster delivery of innovative biologics to patients.

About Bioengineering AG

Bioengineering AG is a global leader in bioreactor technology. With over 50 years of dedicated expertise, the company has built a strong international reputation for professional excellence. Today, Bioengineering AG serves clients worldwide, offering comprehensive solutions that cover the full spectrum of bioreaction and cultivation needs—from laboratory research and pilot-scale development to commercial-scale production. In 2025, Bioengineering AG officially joined the Morimatsu. By synergizing its deep technological foundation with collaborative innovation, the company is committed to driving high-quality, sustainable development across the pharmaceutical, biopharmaceutical, and synthetic biology industries.

About Morimatsu LifeSciences

Morimatsu LifeSciences is a key business segment of Morimatsu International Holdings Limited (Stock Code: 2155.HK). It comprises Shanghai Morimatsu Pharmaceutical Equipment Engineering Co., Ltd., Morimatsu (Suzhou) LifeSciences Co., Ltd., Shanghai Morimatsu Biotechnology Co., Ltd., Shanghai Mori-Biounion Technology Co., Ltd., Shanghai Morisora Technology Co., Ltd., Bioengineering AG, Pharmadule Morimatsu AB, and its affiliated companies.

Morimatsu LifeSciences is dedicated in providing core equipment, process systems, and smart modular facility solutions, and services for the pharmaceutical, biopharmaceutical, medical aesthetics, and fast-moving consumer goods (FMCG) sectors including (cosmetics, food, and health supplements), as well as data centers.

Our team comprises highly experienced professionals with deep expertise in process R&D, engineering design, advanced manufacturing, compliance and validation consulting, production execution, and intelligent operations. With broad experience across diverse industries, we fully understand the unique characteristics and process requirements of various products. This enables us to deliver tailored, end-to-end process solutions from the conceptual design stage, precisely aligned with client’s specific needs.

Morimatsu LifeSciences has established a strong global presence, supported by advanced R&D centers, design hubs, and state-of-the-art manufacturing facilities worldwide. Our well-established service network spans Europe,USA,Asia-Pacific, and emerging markets. We have successfully delivered outstanding, customized solutions to clients in over 40 countries and regions, gaining extensive experience in international project execution.

As a multinational enterprise with core strengths in process technology, modular facility construction, and intelligent manufacturing, Morimatsu LifeSciences is dedicated to meeting the evolving equipment and system needs of our key industries. Through continuous innovation and technological advancement, we are steadily expanding our global footprint, driving our international strategy forward, and delivering Morimatsu’s expertise, reliability, and innovation to the global life sciences and related sectors.